Patient characteristics of new-user GLP-1RA cohort before and after propensity score matching
| GLP-1RA new user cohort before propensity score matching | GLP-1RA new user cohort after propensity score matching | |||
| GLP-1RA (n=501) | SU (n=16 409) | GLP-1RA (n=488) | SU (n=488) | |
| Age in years (SD) | 49.4 (11.3) | 57.8 (12.9) | 49.7 (11.2) | 49.2 (12.6) |
| Female | 204 (40.7%) | 6021 (36.7%) | 198 (40.6%) | 174 (35.7%) |
| Measure of deprivation | ||||
| Least | 40 (8%) | 1688 (10.3%) | 40 (8.2%) | 29 (5.9%) |
| Most | 56 (11.2%) | 1770 (10.8%) | 56 (11.5%) | 52 (10.7%) |
| Unknown | 240 (47.9%) | 6784 (41.3%) | 230 (47.1%) | 214 (43.9%) |
| Diabetes duration in years (SD) | 1.7 (1.6) | 1.2 (1.6) | 1.7 (1.6) | 1.7 (1.8) |
| Body mass index >30 | 470 (93.8%) | 10 481 (63.9%) | 458 (93.9%) | 452 (92.6%) |
| No of hospitalisations in year prior to cohort entry | ||||
| 0 | 456 (91%) | 14 170 (86.4%) | 445 (91.2%) | 437 (89.5%) |
| 1 | 29 (5.8%) | 1344 (8.2%) | 28 (5.7%) | 27 (5.5%) |
| 2 | 10 (2%) | 499 (3%) | 9 (1.8%) | 17 (3.5%) |
| 3+ | 6 (1.2%) | 396 (2.4%) | 6 (1.2%) | 7 (1.4%) |
| No of drugs in year prior to cohort entry | ||||
| 0–4 | 17 (3.4%) | 1660 (10.1%) | 17 (3.5%) | 18 (3.7%) |
| 5–10 | 195 (38.9%) | 7899 (48.1%) | 192 (39.3%) | 208 (42.6%) |
| 11+ | 289 (57.7%) | 6850 (41.7%) | 279 (57.2%) | 262 (53.7%) |
| HbA1c | ||||
| <6.5% | 66 (13.2%) | 1085 (6.6%) | 62 (12.7%) | 66 (13.5%) |
| 6.5%–7.5% | 99 (19.8%) | 2593 (15.8%) | 97 (19.9%) | 99 (20.3%) |
| 7.5%–9% | 150 (29.9%) | 5357 (32.6%) | 145 (29.7%) | 134 (27.5%) |
| 9%+ | 179 (35.7%) | 7068 (43.1%) | 177 (36.3%) | 178 (36.5%) |
| Unknown | 7 (1.4%) | 306 (1.9%) | 7 (1.4%) | 11 (2.3%) |
| eGFR <60 | 36 (7.2%) | 2821 (17.2%) | 35 (7.2%) | 40 (8.2%) |
| Diagnoses in year prior to cohort entry | ||||
| Heart failure | 5 (1%) | 244 (1.5%) | 5 (1%) | 6 (1.2%) |
| Hypertension | 107 (21.4%) | 3398 (20.7%) | 106 (21.7%) | 104 (21.3%) |
| Dyslipidaemia | 16 (3.2%) | 771 (4.7%) | 16 (3.3%) | 23 (4.7%) |
| Ischaemic heart disease | 11 (2.2%) | 644 (3.9%) | 11 (2.3%) | 9 (1.8%) |
| Peripheral vascular disease | S | 106 (<1%) | S | S |
| Prescription drug use in year prior to cohort entry | ||||
| Metformin | 457 (91.2%) | 13 542 (82.5%) | 445 (91.2%) | 449 (92%) |
| Acarbose | S | 7(<1%) | S | S |
| SGLT2 inhibitors | 5 (1%) | 87(<1%) | 5 (1%) | 5 (1%) |
| Meglitinide | 11 (2.2%) | 39(<1%) | 10 (2%) | 10 (2%) |
| Thiazolidinedione | 38 (7.6%) | 376 (2.3%) | 38 (7.8%) | 41 (8.4%) |
| Insulin | 65 (13%) | 307 (1.9%) | 55 (11.3%) | 59 (12.1%) |
| Hypnotic | 32 (6.4%) | 1093 (6.7%) | 32 (6.6%) | 35 (7.2%) |
| Mood | 10 (2%) | 228 (1.4%) | 10 (2%) | 8 (1.6%) |
| Anticonvulsant | 33 (6.6%) | 682 (4.2%) | 31 (6.4%) | 32 (6.6%) |
| Antipsychotics | 12 (2.4%) | 507 (3.1%) | 12 (2.5%) | 12 (2.5%) |
S, suppressed due to low number of events.
DPP-4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin A1c; SGLT2, sodium-dependent glucose cotransporter-2; SU, sulfonylureas.